Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Zai Lab Limited

Market Cap 1.92B 1.65B 1.52B 1.43B 2.68B 181B 2.71B 17.99B 7.03B 88.76B 7.2B 7.04B 307B P/E Ratio 2026 *
-7.71x
P/E Ratio 2027 * -9.15x
Enterprise Value 1.47B 1.27B 1.17B 1.1B 2.06B 139B 2.08B 13.83B 5.4B 68.25B 5.53B 5.42B 236B EV / Sales 2026 *
3.29x
EV / Sales 2027 * 2.57x
Free-Float
95.17%
Yield 2026 *
-
Yield 2027 * -
1 week+2.80%
Current month-2.65%
1 month-11.45%
3 months-10.37%
6 months-2.65%
Current year-0.68%
1 week 13.6
Extreme 13.6
15.4
1 month 13.5
Extreme 13.5
18.2
3 years 12.6
Extreme 12.6
38.2
5 years 12.6
Extreme 12.6
149
Manager TitleAgeSince
Chief Executive Officer 60 01/04/2014
Director of Finance/CFO 58 07/07/2023
President 62 01/12/2022
Director TitleAgeSince
Chairman 60 01/04/2014
Director/Board Member 82 01/01/2017
Director/Board Member 74 01/01/2017
Change 5-day change 1-year change 3-year change Capi.($)
+4.08%+2.80%-60.48%-42.58% 1.92B
-0.03%+0.28%+17.29%-21.71% 62.28B
-5.71%-0.69%+60.05%+205.66% 60.59B
+2.86%+33.20%+33.20%+33.20% 39.55B
-1.84%+7.78%-55.82%-63.26% 36.8B
-1.02%+2.87%+51.21%-33.47% 29.53B
-5.81%+1.91%+44.01%+63.89% 21.68B
+1.67%+6.39%+94.77%-61.04% 19.8B
+1.24%+1.04%-4.09%+126.32% 16.96B
-0.96%-2.03%+50.73%+97.91% 16.16B
Average -1.07%+2.89%+23.09%+30.49% 33.71B
Weighted average by Cap. -1.38%+2.77%+29.32%+42.34%

Financials

2026 *2027 *
Net sales 449M 387M 356M 334M 627M 42.41B 633M 4.21B 1.64B 20.77B 1.68B 1.65B 71.86B 596M 513M 472M 443M 833M 56.29B 841M 5.59B 2.18B 27.56B 2.24B 2.19B 95.38B
Net income -241M -208M -191M -179M -337M -22.77B -340M -2.26B -882M -11.15B -904M -885M -38.58B -156M -135M -124M -116M -219M -14.79B -221M -1.47B -573M -7.24B -587M -575M -25.06B
Net Debt -443M -382M -352M -330M -619M -41.88B -626M -4.16B -1.62B -20.51B -1.66B -1.63B -70.97B -387M -334M -307M -288M -541M -36.59B -547M -3.63B -1.42B -17.92B -1.45B -1.42B -62.01B
Logo Zai Lab Limited
Zai Lab Ltd is a holding company primarily engaged in biopharmaceutical business. The Company is focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. The Company has a series of patented drug candidates from the discovery stage to the late clinical project, including ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others. The Company conducts its businesses within domestic and overseas markets.
Employees
-
Date Price Change
16/06/26 15.20 +3.40%
12/06/26 14.70 -3.29%
11/06/26 15.20 +2.01%
10/06/26 14.90 +3.47%
09/06/26 14.40 +0.70%
Trader
Investor
-
Global
-
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
17.07USD
Average target price
33.30USD
Spread / Average Target
+95.10%

Quarterly revenue - Rate of surprise

- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!